1 / 39

How to Navigate the IRB Process

How to Navigate the IRB Process. Todd Rice, M.D., M.Sc. Vanderbilt Institutional Review Board Chair, Health Sciences Committee #2. Outline. Overview of the IRB Type of Research / Reviews Behavioral vs. Health Sciences Non-human subject and non-research

sohalia
Download Presentation

How to Navigate the IRB Process

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. How to Navigate the IRB Process Todd Rice, M.D., M.Sc. Vanderbilt Institutional Review Board Chair, Health Sciences Committee #2

  2. Outline • Overview of the IRB • Type of Research / Reviews • Behavioral vs. Health Sciences • Non-human subject and non-research • Exempt vs. Expedited vs. Full-Committee Reviews • Vulnerable Populations • The journey of a research proposal

  3. Institutional Review Boards • In response to many research and ethical controversies, Congress passed the National Research Act of 1974 • Established the modern IRBs • Established the federal regulations and policies for IRB oversight of human subjects research (45 CFR 46) • Established the “National Commission for Protection of Human Subjects of Biomedical and Behavioral Research” (OHRP)

  4. Institutional Review Boards • Overseen by Office of Human Research Protection (OHRP) which is a division of the Health and Human Services (DHHS) • OHRP is separate from the Food and Drug Administration (FDA) • Mission of the IRB: Ensure the protection and welfare of human subjects • Each Committee composed of: • Physicians • Non-physician Scientists • Community Members

  5. IRB Oversight • Non-human Subjects Research • Human subjects research • Clinical Investigation • Diagnostic or Therapeutic Procedures • Novel interventions or treatment modalities • Data Repositories • Humanitarian Use Devices • Emergency Use of investigational drugs or devices • Case Studies • Internet Research • Pilot Studies

  6. 2005 Total submissions: 7004 New Studies: 1252 Non-human / non-research: 102 Exempt: 408 Expedited: 306 Standard: 345 Misc: 91 2004 Total submissions: 6172 New Studies: 1104 Non-human / non-research: 34 Exempt: 326 Expedited: 276 Standard: 348 Misc: 120 IRB Numbers

  7. (615) 322-2918

  8. Investigator Training • Complete training in human subjects research • CITI program • NIH program- not a substitute for CITI • Continuing education (training) annually • IRB “News You Can Use” sessions • CITI modules

  9. “I’m Just a Research Proposal…” The long journey to becoming an “IRB Approved Study” With apologies to Schoolhouse Rock

  10. Types of IRB Determinations • Not Research • Research = systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge 45 CFR 46.102(d) • Quality Assurance Projects • Non-human Subjects • Human subject = a living individual about whom an investigator obtains either data through an intervention or interaction with the individual or identifiable private information 45 CFR 46.102(f) • De-identified specimens from repository • Tenncare database research

  11. Types of IRB Determinations • Exempt – 6 categories • Educational tests, surveys, interviews, observations • Collection or study of existing data (retrospective) • Expedited – must be no more than minimal risk • Does not need full committee review • Categories: • Prospective, non-invasive collection of biological specimens (saliva, urine) • Blood draws – 550 ml / 8 wks; ≤ 2 draws / wk or 50 cc (3 cc/kg) • Collection of data through non-invasive procedures (MRI, EEG) • Research involving materials collected for non-research purposes • Data from voice, video, digital or image recordings • Standard (i.e. Full-committee) – greater than minimal risk • Pharmaceutical studies • Device studies • Intervention studies

  12. Components of Research Proposal • Protocol • IRB Application • Informed Consent Form(s) • Vulnerable Population Form(s) • HIPAA Authorization Form • ± HSRC Form • ± Conflict of Interest Declaration Form • ± Investigator’s Brochure

  13. Research Protocol • Every research proposal should have a protocol • Templates are available on IRB website • The protocol should be followed rigidly • Don’t view it as a “guide” that you can be flexible with • Build flexibility into the protocol

  14. IRB Application • The form should be typewritten (not handwritten) • Use the available online instructions • Don’t forget to fill in the header • Students, Residents, and Fellows can be PI of the study, but must have a faculty advisor

  15. IRB Application: Pitfalls • If it meets an expedited criteria, request expedited review (#5) • If the study is associated with another study, list the associated study (#5) • Are you functioning as a coordinating center for the study? (#6)

  16. IRB Application: Pitfalls • Additional VU Committee Approvals (#7) • HSRC –if any radiation for research • GCRC –if using GCRC facilities • SRC –any study involving cancer patients • Biosafety Committee –if study involves gene transfer or uses live virus • These can be pending when the original application is submitted

  17. IRB Application: Pitfalls • Purpose and Background – put in lay terms for committee (#9,10) • Number to be consented vs. number to participate beyond screening (#11) • Don’t target gender, race, etc. unless justification (principle of justice) (#12) • If population is high risk for incarceration, consider applying for prisoner approval

  18. IRB Application: Pitfalls • Does person obtaining consent have relationship with participants? (#19c) • Therapeutic misconception • Consider another person obtain consent • Put all research procedures and who will pay for them in table for q23. • Every study needs Data and Safety Monitoring Plan • No such thing as “no risk” study • Monitoring may be as simple as PI will monitor the study for AEs and submit to IRB

  19. Writing an ICD – General Tips • Avoid exculpatory language • “You must…” or “You have to…” or language indicating they “waive” any rights • Avoid the phrase “Free of Charge” • Instead, use “at no cost to you” • Don’t forget to fill out the header • Keep length to as short as possible • Longer consents = less comprehension 1-3 1Grossman SA, et al. J Clin Oncol. 1994;12:2221-5. 2Sharp SM. Am J Clin Onc. 2004;27:570-5. 3Joseph RR. Cancer. 1994:74(suppl):2692-3.

  20. Informed Consent Documents • Use the VU IRB template • Covers all the required elements • Write the ICD in the second person • “You are being asked to…”, “side effects you may feel…”, “your child…” • Identify procedures that are investigational vs. standard of care

  21. Informed Consent Documents • Don’t re-invent the wheel – use IRB approved template language if possible • Adverse Event language • Allergic reaction language • Conscious Sedation language • MRI language • Genetic rider • Pregnancy language • Chemotherapy language • High risk disease language • Lidocaine language http://www.mc.vanderbilt.edu/irb/IRBForms.htm

  22. Informed Consent Documents • “Keep it simple stupid” • Language must be written at or below 8th grade level • Use short words – 2 syllables or less • Use short sentences with bullets • Use lay terms, or at least put in parentheses (www.medterms.com) • Smog readability tool:www.cdc.gov/od/ads/smog.htm • Fleisch Kincaid Readability in MS Word • Tools – Options – Spelling/Grammar –check show readability statistics

  23. Writing an ICD – Item # 4:Risks, Discomforts, Inconveniences • Separate into sections by medicine or procedure (risks of blood draw, etc.) • Reporting of side effect frequencies is determined locally • Common > 10 % • Uncommon 1-10 % • Rare < 1% - only need to list serious / life-threat • Also note any AEs that may be serious or life-threatening * • If don’t know, tell the participant what you do know – “one person has died…”

  24. Writing an ICD – Item # 4:Risks, Discomforts, Inconveniences • Use lay terms, or at least put in parentheses (www.medterms.com) • Do not need to include treatments for side effects, unless they are routinely given (i.e. anti-emetics, etc.) • Requirement for including risks of standard of care (SOC) procedures will vary • If being consented for SOC procedure separately, state so in study ICD

  25. Writing an ICD – Item #3Costs to You for taking part • Tell participants if they will have added cost • “You or your insurance will be billed for standard of care procedures” • “The sponsor is paying for … or ___ will be given to you at no extra cost” • Use Vanderbilt template language for insurance may not cover costs associated with research

  26. Writing an ICD – Payment in Cases of Injury (#6) • Explain if any compensation or medical treatment is available for injury • Who will pay • What treatment will be covered • Only immediate and necessary • No additional monies for loss of wages • Use adverse event / immediate necessary care template language • Varies with contract language for industry-supported studies – submit contract

  27. Writing an ICD – Items #7a & 7bBenefits to Participants or Others • Make them aware if no personal benefit • Avoid “your taking part will benefit others” • “instead, the results of this study, will help..” • Put “but no promises can be made” at the end of any possible benefits

  28. Writing an ICD – Item #9“Payments” for Participation • The FDA and OHRP state these should be “re-imbursements” for time and inconvenience • Must be “reasonable” for procedures in the study and not coercive • They should be pro-rated over the course of the study • Do not have to be exactly equal. Can “reimburse” more for finishing the whole study • Payment is NOT a benefit of taking part in the study • If total payment > $600, put template language about being taxable and reported to IRS

  29. Vulnerable Populations • Children • Need child assent & parental consent form • Cat 1 = minimal risk; Cat 2 = > min risk, benefit • Cat 3 = “slightly > min risk”, no benefit; • Cat 4 = > min risk and no possibility for benefit • Pregnant Females • Prisoners – if not approved, must withdrawal * • Cognitively Impaired (Decisionally impaired) • Unimpaired population cannot be substituted • Surrogate consent • Need for ombudsman

  30. After Initial Submission… • Within 1-3 weeks, will get PA pre-review • respond to all requests / questions • After response to pre-review, will go to full-committee within 1-2 weeks • Deferred, Approved pending, or Approved • Respond to all concerns • FINAL APPROVAL with STAMPED CONSENT FORMS

  31. After Obtaining Approval • Continuing review must occur at least annually • Amendments must be submitted for any changes to the application, protocol, study personnel, or informed consent • Protocol Violations should be submitted as adverse events • Serious Adverse Events (unexpected, serious, related) need to be submitted when they occur • Other Adverse Events submitted as summary at time of continuing review

  32. Continuing Review • Continuing review form • Notices sent out 8 weeks in advance • Submit early to allow time to resolve any questions or issues • Cover letter with summary of study procedures • If not re-approved by expiration date, study will expire for lapse

  33. Continuing Review • On Continuing review form, include # of patients consented, enrolled, withdrawn • Submit summary of AEs • Report any problems or unexpected events • Submit DSMB or other safety reports • Problems recruiting • May get asked for explanation if no enrollment

  34. Amendments • Amendment form • Submit whenever something changes • If minor, may be handled in expedited fashion if no change to ICF • Provide detailed summary of changes • Form also used for submission of reports • DSMB, Safety committees

  35. Adverse Events • Adverse Event form • Submit serious, unexpected, and related AEs in “timely fashion” • If outside Vanderbilt, only need to submit in real time if changes required to consent form • Protocol violations submitted as AEs • If medwatch report submitted to FDA, attach report in lieu of answering questions 4-10

  36. Adverse Events • Must choose one of the following: • Currently described as risk in ICD • Not described as risk and no need for revision to ICD because … • Give reason for investigator belief that it doesn’t need to be in ICD (i.e. not related, etc.) • Not described as risk but revision to ICD needed

  37. Finishing Up an Approved Study • If no longer enrolling, won’t get stamped consent form (Unless new risks to communicate to pts) • Still receiving research interventions (i.e. study blood draws, study procedures) • Only long-term follow-up (i.e. all procedures std of care) • Only data analysis (no interaction with patients) • Close study – provide summary report

  38. QUESTIONS?? Useful Resources: IRB www.mc.vanderbilt.edu/irb Phone: 322-2918 (ask for protocol analyst or the Process Improvement Team) Research Support Services http://www.mc.vanderbilt.edu/root/vumc.php?site=support Phone: 322-7343

More Related